Viking Therapeutics (VKTX) EBITDA (2014 - 2026)
Viking Therapeutics (VKTX) posted EBITDA of -$132.6 million for Q2 2026, up 19.21% sequentially from -$164.1 million in Q1 2026, and down 77.81% YoY from -$597.4 million in Q2 2025.
Viking Therapeutics (VKTX) EBITDA (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported EBITDA for 13 years, with the latest figure at -$132.6 million in Q2 2026.
- Quarterly EBITDA fell 77.81% year-over-year to -$132.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$560.0 million (down 163.12% YoY) and the FY2025 annual result came in at -$393.3 million, down 160.63% from the prior year.
- EBITDA advanced to -$132.6 million in Q2 2026 per VKTX's latest filing, from -$164.1 million in the prior quarter.
- Over five years, EBITDA peaked at -$16.2 million in Q3 2022 and troughed at -$164.7 million in Q4 2025.
- A 5-year average of -$56.2 million and a median of -$34.1 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA dropped 13.45% in 2022, then tumbled 256.28% in 2025.
- Over 5 years, EBITDA stood at -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plunged by 57.89% to -$46.2 million in 2024, then sank by 256.28% to -$164.7 million in 2025, then gained by 19.51% to -$132.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$132.6 million, -$164.1 million, and -$164.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -132.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132.60 Mn |
| Mar 31, 2026 | -164.13 Mn |
| Dec 31, 2025 | -164.74 Mn |
| Sep 30, 2025 | -98.56 Mn |
| Jun 30, 2025 | -74.57 Mn |
| Mar 31, 2025 | -55.47 Mn |
| Dec 31, 2024 | -46.24 Mn |
| Sep 30, 2024 | -36.56 Mn |
| Jun 30, 2024 | -34.05 Mn |
| Mar 31, 2024 | -34.07 Mn |
| Dec 31, 2023 | -29.29 Mn |
| Sep 30, 2023 | -27.27 Mn |
| Jun 30, 2023 | -23.74 Mn |
| Mar 31, 2023 | -20.54 Mn |
| Dec 31, 2022 | -20.28 Mn |
| Sep 30, 2022 | -16.20 Mn |
| Jun 30, 2022 | -17.63 Mn |
| Mar 31, 2022 | -16.25 Mn |
| Dec 31, 2021 | -12.51 Mn |
| Sep 30, 2021 | -13.40 Mn |